X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

European Medicines Agency Ends COVID-19 Prioritization Plan

Content Team by Content Team
13th May 2023
in News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The European Medicines Agency (EMA) and the European Medicines regulatory network have announced the lifting of COVID-19 business continuity measures, signifying a step towards normalizing regulatory processes as pandemic trends shift. These measures were introduced in 2020 to prioritize the assessment of COVID-19 therapeutics and vaccines, and as a part of this, COVID-19 medicines were given priority in various pharmacovigilance procedures.

Now, the EMA plans to systematically reinstate the activities and processes that were previously suspended or scaled back due to the pandemic. This gradual restoration of operations is a positive indication of progress towards resuming normal regulatory functions. Additionally, the EMA has set its sights on restarting the publication of clinical data for new active substances in the coming months.

The European medicines regulatory network has in it regulatory agencies from the member states of the European Economic Area. These member states encompass all the countries of the European Union, along with Iceland, Liechtenstein, and Norway, which are not EU members. This network brings together the regulatory authorities of these countries to collaborate and harmonize their efforts in overseeing the safety and efficacy of medicines within the EEA region.

In the global response to the COVID-19 pandemic, the recent announcement aligns with actions taken by the World Health Organization (WHO) and US authorities. President Joe Biden signed a resolution ending the COVID-19 national emergency, and the US Public Health Emergency ended on May 11. WHO’s Director-General, Tedros Adhanom Ghebreyesus, emphasized that while COVID-19 remains a health concern, it no longer holds the status of a public health emergency of international concern.

EMA’s Executive Director, Emer Cooke, sees this announcement as a major milestone and emphasizes that the agency will adapt its approach accordingly. Leveraging the lessons gained from the COVID-19 pandemic, the EMA aims to influence its strategy in various domains. In particular, it will concentrate on anti-cancer medicines this year to effectively apply the knowledge obtained. The European Medicines Agency’s programming document for 2025 highlights six critical areas of emphasis, demonstrating their commitment to ensuring the availability of medicines and addressing the risks posed by antimicrobial resistance and other emergencies.

Previous Post

Rising Pharmaceuticals Demand Drives Tablet Coatings Market

Next Post

Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience

Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In